Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 540788 | NSE Symbol : | ISIN : INE500C01017 | Industry : Healthcare |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
31-Jan-2025	07-Feb-2025	Quarterly Results	Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2025 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results for the Quarter and Nine Months ended December 31 2024 Outcome of the Board Meeting dated February 07, 2025 (As per BSE Announcement Dated on 07/02/2025)
29-Oct-2024	12-Nov-2024	Quarterly Results	Quarterly Results Unaudited Standalone and Consolidated Financial Results along with Limited Review Report for quarter/half year ended September, 2024 (As Per BSE Announcement Dated on: 12/11/2024)
03-Aug-2024	13-Aug-2024	Quarterly Results	Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2024 inter alia to consider and approve Unaudited Standalone & Consolidated Financial Results for the quarter ended June 30 2024 & other business with the permission of Chair. The Board of Directors in its meeting held today approved Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 ,2024 (As per BSE Announcement dated on 13/08/2024)
18-May-2024	28-May-2024	Accounts	Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2024 inter alia to consider and approve Audited Financial Statements (Standalone) of the Company for the fourth quarter and year ended as on March 31 2024 and to discuss any other matter with the permission of the Chair. Audited Financial Results for the quarter and Financial Year ended March 31, 2024 Appointment of Secretarial Auditor & Internal Auditor of the Company for the Financial Year 2024-2025 (As Per BSE Announcement Dated on 28.05.2024)
01-Feb-2024	13-Feb-2024	Quarterly Results	Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2024 inter alia to consider and approve Unaudited Financial Results for the quarter and nine months ended December 31 2023 and to consider any other matter with the permission of the Chair. The Board Meeting to be held on 10/02/2024 Stands Cancelled. Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 ,inter alia, to consider and approve Unaudited Financial Results for the quarter ended December 31, 2023 in the Board Meeting to be held on February 13, 2024 and to consider any other business with the permission of the Chair. (As per BSE Announcement Dated on 05/02/2024) Unaudited Financial Results for the quarter and nine months ended December 31, 2023. (As per BSE Announcement Dated on 13/02/2024)
28-Oct-2023	11-Nov-2023	Quarterly Results	Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2023 inter alia to consider and approve Standalone Unaudited Financial Results for the quarter and half year ended as on September 30 2023 Financial Results for the Second Quarter and Half Year Ended 30th September,2023 duly approved by the Audit Committee and Board Meeting in its meeting held on November 11, 2023 (As Per BSE Announcement Dated on 11.11.2023) Newspaper Advertisement for Unaudited Financial Results for the quarter and the half year ended September 30, 2023 (As Per BSE Announcement Dated on 13/11/2023)
26-Jul-2023	12-Aug-2023	Quarterly Results	Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2023 inter alia to consider and approve the Unaudited Financial Results of the Company for the Quarter ended 30th June 2023 and to consider any other business with the permission of the Chair. ASPIRA PATHLAB & DIAGNOSTICS LIMITED has informed BSE about Board Meeting to be held on 12 Aug 2023 to consider financial statements for the period ended June 2023. Financial results. Approval of the Financial Results and Limited Review Report for the quarter ended June 30, 2023 Appointment of Mr. Manas Mengar as the Additional Independent, Non-Executive Director of the Company for the period of 5 (Five) Years subject to the approval of members in the General Meeting The Board of Directors in its meeting held today has approved the appointment of Ms. Krupali Shah as the Company Secretary and Compliance Officer of the Company Pursuant to regulation 30 of the SEBI (LODR) Regulations, 2015 the Board of Directors in its meeting held today had discussed following two items 1)To increase the promoter stake in the Company via Open Offer 2) To increase the business tie ups with the Promoter Company M/s. Yashraj Biotechnology Limited However the above items were only discussed in the meeting and shall be finalized only once the formal agreement are acted upon. Further the finalized decisions with respect to above items shall be informed to the Stock Exchange on time to time basis (As per BSE Announcement Dated on 12/08/2023)
20-May-2023	27-May-2023	Accounts	Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2023 inter alia to consider and approve Audited Financial Results for the quarter and financial year ended on March 31 2023. This is to further inform that pursuant to the Companys Code of Conduct for Prohibition of Insider Trading framed in accordance with the SEBI (Prohibition of Insider Trading) Regulations 2015; the trading window for all the Directors Key Managerial Personnel Designated persons and their immediate relatives shall remain closed and will re-open after 48 hours of the declaration of the financial results of the Company for the quarter and year ended 31st March 2023. Pursuant to Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''''Listing Regulations''''), the Board of Directors of the Company at their held on Saturday, 27th May, 2023 which was commenced at 03:30 P.M. and concluded at 05:20 PM. Attached Agenda items were approved in the meeting. Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held on Saturday, May 27, 2023 has approved the appointment of M/s. Nilesh A. Pradhan & Co. LLP, Practicing Company Secretary as a Secretarial Auditor and M/s. Vishal Bhanushali & Associates, Chartered Accountant as an Internal Auditor of the Company. The Information required to be submitted pursuant to Regulation 30 of the Listing Regulations is marked and attached as ''Annexure-A & B''. (As Per BSE Announcement Dated on 27.05.2023)
06-Feb-2023	14-Feb-2023	Quarterly Results	Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 inter alia to consider and approve the unaudited financial results for the quarter ended 31st December 2022 and other business matters. Pursuant to Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''''Listing Regulations''''), the Board of Directors of the Company at their held on Tuesday, 14th February, 2023 which was commenced at 03:30 P.M. and concluded at 04:05 PM. Attached Agenda items were approved in the meeting. (As per BSE Announcement Dated on 14/02/2023)
05-Nov-2022	12-Nov-2022	Quarterly Results	Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2022 inter alia to consider and approve the unaudited financial results for the quarter and half year ended 30th September 2022 and other business matters Pursuant to Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''''Listing Regulations''''), the Board of Directors of the Company at their held on Saturday, 12th November, 2022 which was commenced at 03:30 P.M. and concluded at 04:30 PM. Attached Agenda items were approved in the meeting. (As Per BSE Announcement Dated 12.11.2022)
27-Jul-2022	13-Aug-2022	Quarterly Results	Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2022 inter alia to consider and approve the following: 1) Un-audited Financial Results of the Company for the quarter ended June 30 2022; and 2) Variation/alteration of Preference Shareholders right by converting said unlisted Preference Shares into Compulsorily Convertible Preference Shares and issuance of Equity Shares arising on conversion thereof subject to approval of Preference Shareholders Equity Shareholders and such other regulatory statutory authority (ies) as may be required. 3) To fix date time venue for the 49th Annual General Meeting of the Company. 4) To fix Book Closure date for the purpose of 49th Annual General Meeting of the Company & other matters. Pursuant to Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''''Listing Regulations''''), the Board of Directors of the Company at their held on Saturday, 13th August, 2022 which was commenced at 03:30 P.M. and concluded at 04:45 PM. Attached Agenda items were approved in the meeting. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), this is to inform that Board of Directors of the Company, in their meeting held today i.e. August 13, 2022 has inter-alia considered and approved the unaudited Financial Results for the quarter ended on June 30, 2022. Dear Sir/Madam, Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held on Saturday, August 13, 2022 has approved the Continuation of Directorship of Dr. Subhash Salunke as Independent Director of the Company.The Information required to be submitted pursuant to Regulation 30 of the Listing Regulations is marked and attached as Annexure. (As Per BSE Announcement Dated on 13/08/2022)
21-May-2022	28-May-2022	Accounts	Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2022 inter alia to consider and approve Aspira Pathlab & Diagnostics Limited has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2022 inter alia to consider and approve the Audited financial results of the Company for the quarter and year ended March 31 2022 and other matters. Pursuant to Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''''Listing Regulations''''), the Board of Directors of the Company at their held on Saturday, 28th May, 2022 which was commenced at 03:30 P.M. and concluded at 05:45 PM. Attached Agenda items were approved in the meeting. Dear Sir/Madam, Pursuant to Regulation 30 read with Part A of Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held on Saturday, May 28, 2022 has approved the appointment of Dr. Pankaj Shah as a Managing Director of the Company. The Information required to be submitted pursuant to Regulation 30 of the Listing Regulations is marked and attached as Annexure. Dear Sir/Madam, Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held on Saturday, May 28, 2022 has approved the appointment of M/s. Nilesh A. Pradhan & Co. LLP, Practicing Company Secretary as a Secretarial Auditor and M/s. Vishal Bhanushali & Associates, Chartered Accountant as an Internal Auditor of the Company. The Information required to be submitted pursuant to Regulation 30 of the Listing Regulations is marked and attached as 'Annexure-I & II'. Dear Sir/Madam, Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held on Saturday, May 28, 2022 has approved the Re-appointment of Mr. Avinash Mahajan as Independent Director of the Company.The Information required to be submitted pursuant to Regulation 30 of the Listing Regulations is marked and attached as Annexure. Please find enclosed herewith the outcome of the Meeting of Board of Directors held on May 28, 2022 and the Minutes of the said meeting pursuant to Regulation 31A of the SEBI (LODR) Regulations, 2015, regarding Reclassification of Promoters. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), this is to inform that Board of Directors of the Company, in their meeting held today i.e. May 28, 2022 has inter-alia considered and approved the Audited Financial Results for the year ended on March 31, 2022. Please find attached: Audited Financial Results for the year ended on March 31, 2022 along with statement of Assets & Liabilities and Cash Flow Statement,Auditors'' Report, and Declaration about unmodified opinion in audit report. (As per BSE Announcement Dated on 28.05.2022)
16-Apr-2022	16-Apr-2022	Change in Other Executives	Appointed Ms. Priya Pandey, Associate Member of the Institute of Company Secretaries of India, as the Company Secretary and Compliance Officer and designated as a Key Managerial Personnel of the Company w.e.f. 16th April, 2022.
05-Feb-2022	12-Feb-2022	Quarterly Results	Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2022 inter alia to consider and approve the un-audited financial results of the Company for the quarter ended December 31 2021. Outcome of the Board Meeting held on February 12, 2022 (As Per BSE Announcement Dated on 12.02.2022)
08-Nov-2021	13-Nov-2021	Quarterly Results	Quarterly Results Results-Unaudited Financial Results for quarter ended September 30, 2021 Outcome of Board Meeting held on November 13, 2021 (As Per BSE Announcement dated on 13.11.2021)

1 2

LOGIN HERE

Aspira Pathlab & Diagnostics Ltd

Board Meeting